玉林品牌怎么样 申请店铺

我要投票 玉林在中草药行业中的票数:5 更新时间:2024-11-22
玉林是哪个国家的品牌?「玉林」是 广西玉林制药集团有限责任公司 旗下著名品牌。该品牌发源于广西,由创始人高海恩在1985-11-28期间创立,经过多年的不懈努力和高速发展,现已成为行业的标杆品牌。
玉林怎么样

广西玉林制药集团有限责任公司(原广西玉林制药厂)成立于1956年,2001年底由国有企业改制成有限责任公司,2011年5月变更为广西玉林制药集团有限责任公司。公司现有员工628人,其中中专以上学历各类专业技术人员159人,约占员工总数的25.3%,从事药品生产管理、质量管理的专业技术人员112人,其中高级工程师17人,工程师41人,助理工程师44人,技术员9人,执业药师38人。

集团公司下辖药用胶囊公司、天绿安公司、宏升贸易公司、玉铭中药材公司、玉药广告公司5个子公司。资产约3亿元,年产值约5亿元。公司生产设备精良,主要设备近千台(套),其中国外引进的先进设备50台(套),成为国内同行业中引进技术和设备最早、最多的企业之一。公司地址位于广西玉林市城站路1号,占地244349.4平方米,其中老厂区占地面积110949.平方米,仁厚新生产基地133400平方米。

公司总建筑面积约103000平方米,其中生产用建筑面积55000平方米,仓储面积28000平方米,绿化面积122466.2平方米,绿化面积占厂区面积的30%以上。公司的生产环境整洁优美,厂区分为生产区、辅助生产区、仓储区和办公区,布局合理。厂区道路全部硬化,不起尘,地面、路面及运输等均不对药品生产造成污染。

公司的机构设置主要分为三大块,一是营销中心下设销售部、市场部、督察部、供应部、仓库等;二是技术中心,下设质量部和科研部;三是生产运行中心,下设中药饮片车间、综合提取车间、固体制剂车间、酊水车间,中试车间,设备部等。

公司以中成药生产为主,现有胶囊剂、酊剂等九个剂型70多个品种。并于2003年元月顺利通过了国家药品GMP认证。认证范围包括胶囊剂、片剂、颗粒剂、糖浆剂和酊剂(含外用)五个剂型以及中药提取;2005年6月通过软膏剂、煎膏剂、合剂、搽剂四个剂型的GMP认证检查;此外,在1996~2010年间连续六次通过澳大利亚TGA的GMP认证及复查,为公司产品进一步拓展海外市场打下基础。我公司的生产范围于2004年9月增加了中药饮片,2007年月10月广西区食品药品监督管理局认证中心检查组对我公司进行了药品GMP认证复查,获得了通过。2004年以来,公司又投资1800多万元扩建中药材仓库、酒精仓库、改建配电房、改造中药饮片车间和固体制剂的造粒干燥工序操作间、中试车间及部分新设备的添置和质检精密仪器(高效液相)的添置,进一步改善了药品生产条件和环境,确保我公司生产的药品是在符合GMP要求的状态下进行。在软件方面对以往生产过程中使用的1000多份生产管理和质量管理文件以及相应记录进行了几次修订完善和提高。并多次进行了GMP知识的全员培训,公司的生产和质量管理均按GMP的规范进行。目前生产的剂型仍主要有酊剂、胶囊剂、颗粒剂、片剂、糖浆剂、软膏剂、煎膏剂、合剂、搽剂以及中药饮片等。我们每年定期对公司实施GMP工作情况开展自检,并形成了自检整改报告。通过自检整改,保证公司的药品生产和质量管理软件、硬件条件与GMP规范始终保持一致。

公司的主导品种正骨水收载在《中国药典》2000年版、2005年版和2010年版,鸡骨草胶囊、湿毒清胶囊、云香精、珍黄丸、睡安胶囊、乌军治胆片、草香胃康胶囊、银蒲解毒片等也收载于《中国药典》2010年版。并在国内外均享有较高声誉。还有30多个品种列入国家非处方药目录和医保目录。产品结构合理,疗效可靠,市场潜力巨大。公司是全国五十强中药生产企业之一,广西的两家中华老字号企业之一、广西百强工业企业之一,广西经济效益先进企业。2006年被国家商务部授予“中华老字号”称号;2007年“玉林牌”商标被评为中国驰名商标;从1988年起被国家授予自营进出口权,公司在全国以及东南亚国家和港、澳、台地区均有一定的知名度。

公司以“质量、市场、成本、效益”为办厂方针,始终将产品质量放在第一位,并将实施药品GMP作为一个新的起点,全面提高员工的质量意识和业务技术素质,提高企业管理水平,为人民的医药健康事业发展作出更大的贡献。

Guangxi Yulin Pharmaceutical Group Co., Ltd. (formerly Guangxi Yulin pharmaceutical factory) was established in 1956. At the end of 2001, it was transformed from a state-owned enterprise into a limited liability company, and changed into Guangxi Yulin Pharmaceutical Group Co., Ltd. in May 2011. At present, the company has 628 employees, including 159 professional and technical personnel with technical secondary school degree or above, accounting for 25.3% of the total number of employees. There are 112 professional and technical personnel engaged in drug production management and quality management, including 17 senior engineers, 41 engineers, 44 assistant engineers, 9 technicians and 38 licensed pharmacists. Under the jurisdiction of the group company, there are five subsidiaries: pharmaceutical capsule company, tianlu'an company, Hongsheng trading company, Yuming traditional Chinese medicine company and Yuyao advertising company. The assets are about 300 million yuan and the annual output value is about 500 million yuan. The company has excellent production equipment, with nearly 1000 sets of main equipment, including 50 sets of advanced equipment imported from abroad, becoming one of the earliest and most introduced enterprises in the same industry in China. The company is located at No.1 Chengzhan Road, Yulin City, Guangxi Province, covering an area of 244349.4 square meters, including 110949. Square meters of the old plant area and 133400 square meters of Renhou new production base. The total building area of the company is about 103000 square meters, including 55000 square meters of production building area, 28000 square meters of storage area, 122466.2 square meters of green area, accounting for more than 30% of the plant area. The production environment of the company is clean and beautiful. The plant area is divided into production area, auxiliary production area, storage area and office area, with reasonable layout. All roads in the plant area are hardened and free from dust. The ground, road surface and transportation will not cause pollution to drug production. The organization of the company is mainly divided into three parts: first, the marketing center consists of sales department, marketing department, supervision department, supply department, warehouse, etc.; second, the technology center consists of quality department and scientific research department; third, the production and operation center consists of herbal medicine decoction workshop, comprehensive extraction workshop, solid preparation workshop, tincture water workshop, pilot plant, equipment department, etc. The company is mainly engaged in the production of Chinese patent medicine, with more than 70 varieties of nine dosage forms including capsule and tincture. In January 2003, it successfully passed the national GMP certification. The certification scope includes five dosage forms of capsule, tablet, granule, syrup and tincture (including external use) as well as extraction of traditional Chinese medicine; in June 2005, it passed the GMP certification inspection of four dosage forms of ointment, decoction, mixture and liniment; in addition, it passed the GMP certification and review of TGA in Australia for six times in 1996-2010, laying a foundation for the company to further expand its overseas market. In September 2004, the production scope of our company increased pieces of Chinese herbal medicine. In October 2007, the inspection team of the certification center of Guangxi food and Drug Administration reviewed the GMP certification of our company and obtained the approval. Since 2004, the company has invested more than 18 million yuan to expand the warehouse of traditional Chinese medicine, the warehouse of alcohol, the transformation of power distribution room, the transformation of traditional Chinese medicine workshop and the operation room of granulation and drying process of solid preparation, the addition of pilot plant and some new equipment, and the addition of quality inspection precision instruments (high-performance liquid phase), further improving the pharmaceutical production conditions and environment, Ensure that the drugs produced by our company are in compliance with GMP requirements. In terms of software, more than 1000 production management and quality management documents and corresponding records used in the previous production process have been revised, improved and improved several times. And has carried on the GMP knowledge many times the entire staff training, the company's production and the quality management all carried on according to the GMP standard. At present, the main dosage forms are tinctures, capsules, granules, tablets, syrups, ointments, decoctions, mixtures, liniments and pieces of Chinese medicine. We conduct self inspection on GMP implementation of the company on a regular basis every year, and form self inspection rectification report. Through self inspection and rectification, ensure that the company's pharmaceutical production and quality management software and hardware conditions are consistent with GMP specifications all the time. The leading bone of the company is bone water collected in China Pharmacopoeia 2000, 2005 and 2010. Chicken bone grass capsule, wet poison capsule, Yun Xiang Jing, Zhen Huang pill, sleep pill, Wu Jun Zhi Dan tablet, Cao Xiang Wei Kang capsule, Yin Pu detoxification tablet are also collected in the 2010 edition of China Pharmacopoeia. And enjoy a high reputation at home and abroad. There are more than 30 varieties listed in the national over-the-counter drug catalog and medical insurance catalog. The product structure is reasonable, the curative effect is reliable and the market potential is huge. The company is one of the top 50 traditional Chinese medicine production enterprises in China, one of the two time-honored Chinese enterprises in Guangxi, one of the top 100 industrial enterprises in Guangxi, and an advanced enterprise with economic benefits in Guangxi. In 2006, it was awarded the title of "China Time-honored Brand" by the Ministry of Commerce of the people's Republic of China; in 2007, it was awarded the title of "Yulin brand" as a well-known trademark in China; since 1988, it has been granted the right of self import and export by the state, and the company has a certain reputation in the whole country and Southeast Asian countries, Hong Kong, Macao and Taiwan. The company takes "quality, market, cost and benefit" as the policy of running the factory, always puts product quality first, and takes the implementation of GMP as a new starting point, comprehensively improves the quality awareness and professional and technical quality of employees, improves the management level of the enterprise, and makes greater contribution to the development of the people's medical and health undertakings.

本文链接: https://brand.waitui.com/a6ebebba2.html 联系电话:07753892003

千城特选小程序码

7×24h 快讯

核聚变产业受青睐,多家公司早已涉足

近期,国务院国资委在署名文章中提出超前布局梯次培育量子科技、核聚变、生物制造、6G等未来产业,再次点燃市场对核聚变产业的热情。11月20日,上海未来聚变能源科技有限公司成立,从股东结构来看,其背后有上海电气控股集团有限公司等3家上海国资旗下公司力挺。环顾A股市场,多家上市公司已从产业链不同领域涉足核聚变赛道。昨日,不少投资者在互动平台密集追问旭光电子、合锻智能等上市公司在核聚变领域的技术、产品、项目等最新进展。(上证报)

2小时前

服装零售商Gap上调全年业绩预期

据报道,服装零售商Gap上调了全年业绩预期,预计本财年销售额将增长1.5%至2%,而此前的预测是增长不到1%,同时上调的还有毛利率和营业收入预测。公司首席执行官理查德·迪克森在接受采访时表示,“从根本上讲,我们的业务比去年要好。”他补充说,该公司的品牌正在“跨类别”抢占市场份额。(界面)

2小时前

“谈生意不再藏着掖着”,期现融合推动化工产业链共赢

在化工贸易环节,上游想把价格卖在高位,下游想把价格买在低位,这种情况长期存在。但随着期货工具的引入,贸易商发挥期现综合服务优势,使用基差贸易等新型模式推动产业链从“对立”走向“共赢”。贸易环节实现深度期现融合,是近年来化工产业的一大变化。近年来,受产能投放周期等因素影响,化工品价格波动幅度较大,产业链企业加工利润被显著压缩。这种情况下,头部贸易商运用期货和衍生品工具带动行业合作共赢,在保障产业链供应链安全稳定方面发挥了积极作用。(上证报)

2小时前

中信建投:低碳环保政策持续完善,全面推进资源循环利用

36氪获悉,中信建投研报称,近期,工信部部长金壮龙发表《进一步全面深化工业和信息化领域改革为推进新型工业化注入强大动力》,提出做强绿色制造业,发展绿色低碳产业,完善绿色环保、新能源装备等发展政策。

2小时前

临近年底,A股易主暗流涌动

临近岁末,A股控制权交易市场暗流涌动。直观来看,“易主”案例近期密集浮现。据不完全统计,10月以来,已有18家上市公司披露交易性控制权变动事项(剔除国资无偿划转、家族内部划转等)。其中,基本面向下、现金流趋紧的公司占据多数,不少公司或面临“戴帽”或“保壳”的压力。水面之下,此前几近沉寂的壳交易,已有买方在摩拳擦掌。多位投行人士反映,近期来咨询买壳事宜的人明显多了起来。(上证报)

2小时前

本页详细列出关于百灵鸟的品牌信息,含品牌所属公司介绍,百灵鸟所处行业的品牌地位及优势。
咨询